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ABSTRACT

Methods: To begin to characterize epidemiologic correlates of antibacterial resistance in
Wisconsin, data analyses were performed with respect to isolates in the Surveillance of
Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE)
2016 collection. In addition to submitting isolates of Escherichia coli, Proteus mirabilis,
Pseudomonas aeruginosa, and Streptococcus pneumoniae, participating laboratories were
also requested to submit data regarding patient age, specimen source, and location of
patient service.
Results: Fifty-five percent of isolates were of outpatient origin (including emergency
department). In general, isolates derived from inpatients were more likely to demonstrate
higher resistance rates than those from outpatient locations. Upon further stratification,
isolates from emergency department encounters generally exhibited higher susceptibility
rates than those from outpatient clinics. Sixty-seven percent of isolates emanated from
skin and soft tissue or invasive sites. Delineation of specimen source played a minimal
role in prediction of antimicrobial resistance. Older patients were more likely to generate
isolates of E coli and P mirabilis exhibiting resistance to agents such as fluoroquinolones and
trimethoprim-sulfamethoxazole.
Conclusions: SWOTARE facilitates epidemiologic investigations into resistance at the local/
state level. Investigations are warranted to further delineate differences in isolates derived
from emergency department and outpatient clinic visits. Characterizations at the demographic
level could impact local empiric treatment guidelines and antimicrobial stewardship
throughout Wisconsin.

T

he Centers for Disease Control and Prevention (CDC)
have recently identified 17 groupings of bacterial and
fungal organisms collectively responsible for at least two million
annual illnesses and 23 000 deaths on the basis of antimicrobial
resistance.1 CDC has additionally advocated a 4 faceted approach
to address the paradigm of national antimicrobial resistance, 1 of
which involves timely surveillance for the emergence of novel and
unique patterns of resistance. The value of such surveillance efforts
has been championed by pioneers in the field.2
We have described implementation of the Surveillance of
Wisconsin Organisms for Trends in Antimicrobial Resistance and
Epidemiology (SWOTARE) program.3 In summary, a centralized
microbiology laboratory assesses representative bacterial isolates
using a standardized antimicrobial susceptibility testing method.
These isolates are submitted by 22 clinical laboratories with
widespread distribution throughout Wisconsin. With such
infrastructure, we currently have capability of monitoring 3 of
the CDC-targeted organism groups.1 Two of these, multidrugresistant Pseudomonas aeruginosa and drug-resistant Streptococcus
pneumoniae, are responsible for 51 000 healthcare-associated
Gundersen Medical Journal • Volume 10, Number 1, December 2017

infections4 and 4 million general infections,5 respectively, on an
annual basis. These infections further translate into resistance rates
approximating 13% to 30%,5,6 with annual deaths attributable
to resistant strains estimated at 440 (P aeruginosa)7 and 7000
(S pneumoniae).5 Furthermore, collected Escherichia coli can be
monitored for evidence of carbapenemase and extended-spectrum
β-lactamase (ESBL) production. It is estimated that these
resistance mechanisms are responsible for greater than 10 000
healthcare-associated infections in the United States annually, with
approximately 700 attributable deaths.4,6-8
An additional component of the SWOTARE program involves
submission of isolate-specific epidemiologic data from participating
clinical laboratories. Such data may not be readily available in
the course of surveillance endeavors strictly involving analysis
of antibiogram data.9 Moreover, as part of the CDC-advocated
surveillance approach,1 it is recommended that data be collected
with respect to risk factors for antimicrobial resistance. This report
provides introductory information relative to the epidemiology of
antimicrobial resistance in Wisconsin, as generated by the 2016
SWOTARE collection.
41
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METHODS

SWOTARE Program

Establishment of the SWOTARE surveillance network, along
with isolate submission and susceptibility testing protocols/
interpretation,10 has been described.3 In summary, clinical
microbiology laboratories in Ashland, Spooner, St. Croix Falls, and
Eau Claire (northwest region); Marshfield, Weston, and Stevens
Point (northcentral region); Manitowoc, Sturgeon Bay, and Green
Bay (northeast region); Platteville, Prairie du Chien, Viroqua,
and La Crosse (southwest region); Fort Atkinson, Janesville,
and Madison (southcentral region); Fond du Lac, Neenah,
and Appleton (Lake Winnebago region); and, West Bend and
Milwaukee (southeast region) participated in the program.

Isolates and Demographic Data

Study sites were requested to collect consecutive isolates
of E coli, Proteus mirabilis, P aeruginosa, and S pneumoniae
identified from in-house culture of clinically significant infection.
Laboratories were further requested to supply limited patient
demographic information, including age, sex, anatomic source,
patient service location, and whether the healthcare encounter
involved an intensive care unit stay. Access to protected health
information for the purpose of the investigation was granted by
the Marquette University Institutional Review Board. Because of
the lack of direct involvement in the collection of specimens and
because of the utilization of de-identified isolates from routine
clinical care, the Review Board did not consider the SWOTARE
program to be actively engaged in human subjects research.

Figure 1. Distribution of isolates assessed by the 2016 SWOTARE
program, delineated by healthcare location of specimen collection.

Data Analysis

Genus-specific
percentage
susceptible,
intermediate
(susceptible-dose dependent for cefepime and Enterobacteriaceae
combinations11), and resistant values, as well as minimum inhibitory
concentration (MIC) determinations (MIC₅₀ and MIC₉₀) were
generated. Such analyses were applied to statewide isolates as
a whole, in addition to characterizations on the basis of patient
healthcare encounter location, specimen source, and patient age.
Only patient service location, specimen source, and age delineations
with n ≥ 25 were utilized for comparisons. The significance test of
proportions determined if differences in susceptibility percentage
were significant. The α level was set at .05 before the investigations
commenced, and all P values are 2-tailed.

RESULTS AND EPIDEMIOLOGIC DISCUSSION

Patient Demographics and Isolate Distribution by
Patient Location

One thousand eighty isolates were submitted to the program
and tested in 2016. Of this total, complete demographic data
were provided for 1055 (97.7%) isolates. Five hundred sixty-one
(53.2%) isolates were derived from women. Mean patient age
was 62.5 years, with a median of 66. Six general patient service
categories (Figure 1) accounted for 94.8% of all patient isolates.
As a result of the inclusion of data from long-term care facilities
as inpatient data, the percentage composition of inpatient isolates
was 45.4%, the largest component of which was internal medicine
(25.6% of all isolates). Outpatient data consisted of outpatient
clinic–derived isolates (30.0% of all isolates) and those collected
from emergency departments (24.6% of all isolates).

42

Figure 2. Distribution of isolates assessed by the 2016 SWOTARE
program, delineated by specimen source.

Isolate Distribution by Specimen Source

Greater than two-thirds of specimens submitted to the
SWOTARE program in 2016 were of skin and soft tissue or
invasive origin (Figure 2). Invasive isolates included those derived
from blood (354 isolates), cerebrospinal fluid (4), paracentesis
fluid (1), hardware (1), bone (1) and bile (1). Sixteen percent of
isolates were derived from urogenital (172 urine, 1 Bartholin cyst)
sources. Distribution of lower respiratory tract isolates (12.6% of
all isolates) included sputum (111), bronchoalveolar lavage (8),
endotracheal aspiration (7), bronchial washings (6), thoracentesis
fluid (3), and pleural fluid (1). Upper respiratory tract isolates
included those derived from ear (18 isolates), nose (9), throat (8),
eye (7), and sinus (4) specimens.

Profile by Patient Location

We compared differences in susceptibility rates for antimicrobial/
organism combinations as a function of patient care location
from which the isolate was derived. Table 1A demonstrates one
example of inpatient isolates exhibiting an increased antimicrobial
Gundersen Medical Journal • Volume 10, Number 1, December 2017
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Table 1. MIC0 and MIC Distributions and Categorical Interpretations of Proteus mirabilis Isolate Susceptibility to Levofloxacin by A: Inpatient
and Outpatient and B: Most Prevalent Patient Locations, Wisconsin 2016
A
CLSI Breakpoints 2/4/8
Location

MIC9

Susceptible

Intermediate

≤0.25

4

89.0

1.9

9.1

≤0.25

>32

69.0

3.4

27.6

≤0.25

16

81.0

2.5

16.5

n

MIC

Outpatient

155

Inpatient

116

Wisconsin

Resistant

B
CLSI Breakpoints 2/4/8
Location

n

MIC

MIC9

Susceptible

Intermediate

Resistant

Clinics

109

Internal Medicine

64

≤0.25

16

86.2

1.8

11.9

≤0.25

>32

67.2

4.7

28.1

Emergency Department
Intensive Care Unit

46

≤0.25

1

95.6

2.2

2.2

10

0.5

8

70.0

10.0

20.0

Long-term Care
Surgery

23

2

>32

65.2

0.0

34.8

13

≤0.25

32

92.3

0.0

7.7

≤0.25

16

81.0

2.5

16.5

Wisconsin

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.

resistance profile over that of outpatient isolates. This inpatient
P mirabilis profile is characterized by a decreased levofloxacin
percentage susceptible value, as well as an elevated MIC₉₀
value. Further subcategorization of this antimicrobial/organism
paradigm is represented in Table 1B. The frank resistance rates and
increased MIC₉₀ values within this profile, as well as a majority
of other antimicrobial/organism profiles (data not illustrated),
justify inclusion of long-term care facilities with inpatient data.
Initial insight into differences in susceptibility between isolates
derived from emergency department visits (95.6% susceptibility)
and those from internal medicine and outpatient clinic encounters
(67.2% and 86.2%, respectively) was also observed.
On the basis of achieved n values, subsequent analysis was
restricted to internal medicine, emergency department, and
outpatient clinics. Greater than 61% of individual E coli,
P mirabilis, P aeruginosa, and S pneumoniae/antimicrobial
combinations revealed susceptibility rates that differed by less
than 10% between the 3 healthcare locations (data not illustrated).
Noteworthy exceptions included a cefazolin susceptibility
difference of 16.1% between emergency department and internal
medicine E coli isolates and a penicillin susceptibility difference
of 22.1% between emergency department and internal medicine
S pneumoniae isolates.
The potential influence of patient service location on
empiric regimen choice is demonstrated in Table 2. For each
of the 4 organisms investigated in the surveillance program, a
higher proportion of antimicrobials demonstrated greater in
vitro potency on emergency department–derived isolates when
Gundersen Medical Journal • Volume 10, Number 1, December 2017

Table 2. Frequency of Antimicrobial/Organism Testing Combinations
Yielding Highest Percentage-Susceptible Values Compared by
Location of Patient Encounter, Wisconsin 2016 a
Patient Encounter Location
Outpatient
Clinic

Internal
Medicine

Emergency
Department

Escherichia coli

18.8

31.3

50.0

Proteus mirabilis

42.9

0.0

92.9

Pseudomonas
aeruginosa

44.4

11.1

55.6

Streptococcus
pneumoniae

0.0

7.7

92.3

Organism

a

Cumulative values may not equal 100% due to rounding or to
multiple patient locations sharing highest percentage-susceptible
value.

compared with outpatient clinic- and internal medicine–derived
isolates. This dichotomy was especially noted with S pneumoniae,
as 92.3% of antimicrobial/emergency department–derived isolate
combinations demonstrated most in vitro potency when compared
with internal medicine- and outpatient clinic–derived isolates
(7.7% and 0%, respectively).
Studies attempting to associate increased antimicrobial
resistance with patient service location have often been performed
in the context of urinary tract infection. In general, healthcare43
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Table 3. Frequency of Percentage Susceptibility Value Differences for
Combinations of Organisms and Antimicrobial Agents Compared by
Top 3 Specimen Sources, Wisconsin 2016 a

associated urinary tract pathogens possess increased resistance
rates when compared with community-acquired agents of urinary
tract infection (particularly with respect to E coli resistance to
fluoroquinolone agents). Examples of such data emanate from
large study collections in international centers that are derived from
antibiogram data12,13 or from surveillance programs.14 From a 4-year
Swiss antibiogram study, Lamoth et al15 reported that communityacquired strains of E coli and P aeruginosa (irrespective of specimen
source) demonstrated higher susceptibility rates when compared to
hospital-acquired strains. With respect to P aeruginosa, this group
further implied that differences in ciprofloxacin and ceftazidime
susceptibility were a function of specific inpatient unit.
Additional investigations have focused on emergency
department populations. Zatorski et al16 compared E coli
antibiograms from non-intensive care unit inpatient urine cultures
with those derived from emergency department patients and
found increased ceftriaxone and ciprofloxacin susceptibility rates
in the latter demographic. Draper et al17 used an antibiogram
approach to determine that emergency department–derived E coli
isolates (regardless of specimen source) demonstrated increased
susceptibility rates to ampicillin, levofloxacin, and trimethoprimsulfamethoxazole when compared with hospital-wide isolates. A
similar paradigm was observed with P aeruginosa and aztreonam.

Maximum
Percentage-Susceptible Difference
Organism

<5%

5-10%

10-20%

>20%

38.9

61.1

0.0

0.0

72.2

16.7

5.6

5.6

Pseudomonas
aeruginosa d

55.6

22.2

22.2

0.0

Streptococcus
pneumoniae e

33.3

53.3

13.3

0.0

Escherichia coli b
Proteus mirabilis

c

Individual specimen source (skin and soft tissue, invasive,
urogenital, lower respiratory, upper respiratory) required 25 isolates
to qualify for this analysis.
b
Top 3 specimen sources were invasive, skin and soft tissue, and
urogenital.
c
Top 3 specimen sources were skin and soft tissue, urogenital, and
invasive.
d
Top 3 specimen sources were skin and soft tissue, invasive, and
lower respiratory.
e
Top 3 specimen sources were invasive, lower respiratory, and upper
respiratory.
a

Profile by Specimen Source

Differences in susceptibility rates were also compared on basis
of specimen source. With respect to each organism, source-specific
n values allowed comparisons among 3 specimen sources. Greater

Table 4. MIC0 and MIC Distributions and Categorical Interpretations of Escherichia coli Isolate Susceptibility to A: Levofloxacin, and B:
Trimethoprim-Sulfamethoxazole by Age, Wisconsin 2016
A
CLSI Breakpoints 2/4/8
Age, y

n

MIC

MIC9

Susceptible

Intermediate

Resistant

20-39

40

≤0.25

0.5

92.5

0.0

7.5

40-59

68

≤0.25

16

80.9

0.0

19.1

60-79

159

≤0.25

32

74.8

0.0

25.2

≥80

90

≤0.25

16

78.9

0.0

21.1

≤0.25

16

79.9

0.0

20.1

Wisconsin

P = .02 for susceptibility rate of 20-39 years versus 60-79 years.
P = .06 for susceptibility rate of 20-39 years versus ≥80 years.
B
CLSI Breakpoints 2/4
Age, y

n

MIC

MIC9

Susceptible

20-39

40

≤1

>16

82.5

17.5

40-59

68

≤1

>16

85.3

14.7

60-79

159

≤1

>16

80.5

19.5

≥80

90

≤1

>16

77.8

22.2

≤1

>16

80.7

19.3

Wisconsin

Intermediate

Resistant

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.
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Table 5. MIC0 and MIC Distributions and Categorical Interpretations of Proteus mirabilis Isolate Susceptibility to A: Ciprofloxacin, and B:
Trimethoprim-Sulfamethoxazole by Age, Wisconsin 2016
A
CLSI Breakpoints 1/2/4
Age, y

n

MIC

MIC9

Susceptible

Intermediate

Resistant

20-39

25

≤0.25

1

92.0

0.0

8.0

40-59

60

≤0.25

16

80.0

1.7

18.3

60-79

110

≤0.25

32

72.7

3.6

23.6

≥80

71

≤0.25

32

67.6

8.5

23.9

≤0.25

32

75.6

4.3

20.1

Wisconsin

P = .04 for susceptibility rate of 20-39 years versus 60-79 years.
P = .02 for susceptibility rate of 20-39 years versus ≥80 years.
B
CLSI Breakpoints 2/4
Age, y

n

MIC

20-39

25

≤1

≤1

100

0.0

40-59

60

≤1

>16

85.0

15.0

60-79

110

≤1

>16

77.3

22.7

≥80

71

≤1

>16

80.3

19.7

≤1

>16

82.4

17.6

Wisconsin

MIC9

Susceptible

Intermediate

Resistant

P = .04 for susceptibility rate of 20-39 years versus 40-59 years.
P = .008 for susceptibility rate of 20-39 years versus 60-79 years.
P = .02 for susceptibility rate of 20-39 years versus ≥80 years.
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.

than 86% of individual E coli, P mirabilis, and S pneumoniae/
antimicrobial combinations exhibited susceptibility rates that
varied by <10% between specimen source (Table 3). In contrast,
22.2% of P aeruginosa/antimicrobial combinations involved
susceptibility variation of >10% between specimen sources.
This was characterized by increased meropenem and aztreonam
susceptibility rates for invasive P aeruginosa isolates (data not
illustrated).
In essence, influence of specimen source on potential empiric
regimen choice was less pronounced than that described for
location of patient encounter. As one example, urogenital isolates
predicted a marginally greater proportion of highly susceptible
antimicrobial agents for P mirabilis (50.0%) when compared
with skin and soft-tissue isolates (35.7%; data not illustrated).
Although participating laboratories were asked to focus collection
efforts on isolates derived from skin and soft tissue, invasive,
and lower respiratory tract sources, lower-volume laboratories
on occasion submitted urinary tract isolates to the SWOTARE
program to fulfill an organism quota. The aforementioned analyses
(ie, marginal susceptibility differences among specimen sources)
suggest that inclusion of this additional specimen source had
minimal impact on regional susceptibility rates and contributed to
overall representative sampling within the geographic area.
Gundersen Medical Journal • Volume 10, Number 1, December 2017

Profile by Patient Age

Finally, age-related determinants of antimicrobial resistance for
each of the 4 surveillance organisms were investigated by focusing
on the 2 to 3 antimicrobial agents with the lowest percentagesusceptible values, as elucidated in a previous report.3 E coli isolates
derived from 20- to 39-year-olds demonstrated more susceptibility
to levofloxacin than those from 60- to 79-year-olds (P = .02; Table
4A). These isolates also trended toward greater susceptibility when
compared with those from patients aged ≥ 80 years (P = .06).
No age-related relationships were noted with trimethoprimsulfamethoxazole (Table 4B) and ampicillin susceptibility.
With respect to P mirabilis, isolates derived from patients aged
20 to 39 years yielded increased rates of ciprofloxacin susceptibility
when compared with isolates from patients aged 60 to 79 years
and ≥ 80 years (P = .04 and P = .02, respectively; Table 5A).
Similarly, P mirabilis isolates from 20- to 39-year-old patients
exhibited increased trimethoprim-sulfamethoxazole susceptibility
when compared with all other age groups (P ≤ .04; Table 5B). No
significant differences were noted when ampicillin susceptibility
was stratified by patient age.
P aeruginosa isolates from 40- to 59-year-old patients exhibited
decreased ciprofloxacin susceptibility when compared with patients
over the age of 60 years (P ≤ .03; Table 6A). Similarly, P aeruginosa
45
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Table 6. MIC0 and MIC Distributions and Categorical Interpretations of Pseudomonas aeruginosa Isolate Susceptibility to A: Ciprofloxacin, and
B: Aztreonam by Age, Wisconsin 2016
A
CLSI Breakpoints 1/2/4
Age, y

n

MIC

MIC9

Susceptible

Intermediate

Resistant

20-39

17

≤0.25

0.5

94.1

0.0

5.9

40-59

48

≤0.25

8

77.1

8.3

14.6

60-79

86

≤0.25

2

90.7

2.3

7.0

≥80

48

≤0.25

1

93.8

0.0

6.3

≤0.25

2

88.2

3.3

8.5

Wisconsin

P = .03 for susceptibility rate of 40-59 years versus 60-79 years.
P = .02 for susceptibility rate of 40-59 years versus ≥80 years.
B
CLSI Breakpoints 8/16/32
Age, y

n

MIC

20-39

17

40-59

48

60-79
≥80
Wisconsin

MIC9

Susceptible

Intermediate

Resistant

8

8

94.1

5.9

0.0

4

32

77.1

10.4

12.5

86

8

16

75.6

17.4

7.0

48

4

16

89.6

6.3

4.2

8

16

81.0

12.3

6.6

P = .05 for susceptibility rate of 60-79 years versus ≥80 years.
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.

isolates derived from patients aged 60 to 79 years demonstrated
less susceptibility to aztreonam than isolates from patients aged
≥ 80 years (P = .05; Table 6B). No significant age delineations were
determined with respect to S pneumoniae susceptibility to either
penicillin (P ≥ .22; Table 7A) or erythromycin (P ≥ .18; Table 7B).
Swami and Banerjee18 used an antibiogram approach to stratify
antimicrobial resistance patterns in E coli and S pneumoniae by
patient age (< 18 years; 18-64 years; ≥ 65 years) at a United States
institution. The authors noted that their institution-wide
antibiogram underestimated resistance profiling in older patients
(particularly with respect to ciprofloxacin and E coli) when
compared with a specialized antibiogram devised for populations
aged ≥ 65 years. In a European study, Grignon et al19 reported
a risk factor for increased ciprofloxacin resistance in emergency
department E coli isolates as being age ≥ 45 years. Data presented in
tables 4 through 7 used an isolate-based approach (stratified over an
increased number of age groupings) to corroborate these findings.
In addition, we were able to extend this paradigm to an additional
member of Enterobacteriaceae (Table 5) with another antimicrobial
class (trimethoprim-sulfamethoxazole; Table 5B). Swami and
Banerjee18 also reported decreased S pneumoniae susceptibility to a
number of antimicrobial classes in pediatric populations. We were
unable to analyze SWOTARE data for a comparative phenomenon
at this time due to low n values for patients under the age of 20
years. Other S pneumoniae comparisons throughout this study
were limited to an extent by disproportionate isolate contributions
across a number of geographic regions.3 Increased isolate quota
46

in future surveillance collections will improve the validity of
antimicrobial-resistant S pneumoniae epidemiologic findings.
In addition to the demographic factors affecting antimicrobial
resistance that are described in this report, one cannot discount
the contribution of geographic location. In the context of the
2016 SWOTARE collection, several geographic paradigms were
noted.3 Grignon et al19 investigated E coli antimicrobial resistance
in the emergency department setting in a region of France
(with population of 3.6 million) with an area equivalent to the
state of Maryland. Of 10 participating emergency departments,
5 were specifically cited as significant risk factors for increased
fluoroquinolone resistance in uropathogenic E coli.
In discussing the current status of antimicrobial resistance
in the United States, the CDC cited gaps in general knowledge
that involved limited national and state capacity for the detection
of emerging antimicrobial resistance trends.1 Past state-based
efforts,20,21 as well as those described within the context of the
SWOTARE program, are therefore necessary to supplement
data generated by national programs. Moreover, the SWOTARE
program already possesses the infrastructure to allow for both
annual assessment of resistance trending and a broadening of
scope via introduction of additional organism groups into the
surveillance paradigm. Boucher et al22 listed a number of pathogens
(vancomycin-resistant Enterococcus faecium, methicillin-resistant
Staphylococcus aureus, ESBL-producing Klebsiella spp. and E coli,
carbapenemase-producing Klebsiella spp., Acinetobacter baumannii,
P aeruginosa, and Enterobacter spp.) for which antimicrobial agent
Gundersen Medical Journal • Volume 10, Number 1, December 2017
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Table 7. MIC0 and MIC Distributions and Categorical Interpretations of Streptococcus pneumoniae Isolate Susceptibility to A: Penicillin, and
B: Erythromycin by Age, Wisconsin 2016
A
CLSI Breakpoints 0.06/0.12*
Age, y

n

MIC

MIC9

Susceptible

20-39

23

≤0.015

0.25

60.9

39.1

40-59

37

≤0.015

2

75.7

24.3

60-79

72

≤0.015

0.5

72.2

27.8

≥80

44

≤0.015

1

68.2

31.8

≤0.015

1

70.3

29.7

Wisconsin

Intermediate

Resistant

B
CLSI Breakpoints 0.25/0.5/1
Age, y

n

MIC

MIC9

Susceptible

Intermediate

Resistant

20-39

23

≤0.06

>4

52.2

0.0

47.8

40-59

37

≤0.06

>4

62.2

0.0

37.8

60-79

72

2

>4

48.6

0.0

51.4

≥80

44

≤0.06

>4

52.3

0.0

47.7

≤0.06

>4

54.2

0.0

45.8

Wisconsin

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibitory concentration in µg/mL.
*Breakpoints for meningeal S pneumoniae isolates.

research and development efforts have become
increasingly necessary. Before such advancements
are made, close surveillance of currently available
agents is essential. The SWOTARE program
currently allows for statewide monitoring of 3
of the 7 aforementioned ESKAPE pathogens in
Wisconsin, as well as 1 additional pathogen cited by
the World Health Organization as another focus for
development of alternative antimicrobial strategies.23

CONCLUSIONS

A number of approaches have been considered in
the monitoring of antimicrobial resistance patterns.
One advantage of a surveillance paradigm based on
isolate collection, such as the SWOTARE program, is
its capability of ascribing demographic information
to isolates. Testing within the SWOTARE program
in 2016 revealed resistance variation with respect to
a number of antimicrobial/organism combinations.
These differences were more relative to location of
patient encounter and patient age when compared
with specimen source. Year 1 of this surveillance
project also revealed particular niches of potential
emerging resistance that will be assessed in future
seasons of isolate collection. All told, provision of
these data to a broad audience may potentiate revision
of local empiric therapy guidelines and contribute to
antimicrobial stewardship efforts.

ACKNOWLEDGMENTS

Partial funding was granted by Marquette University College of Health
Sciences. The authors are grateful to the following individuals for provision
of isolates for the 2016 surveillance project and for additional coordinative
assistance for this program:
Jorn Bansberg, Viroqua

Brooke Olson, Marshfield

Eric Beck, PhD, Milwaukee

Ray Podzorski, PhD, Madison

Tim Block, West Bend

Mattie Pitts, Spooner

Erin J. Bowles, Madison

Lynn Prellwitz, Manitowoc

Becky Brooks, Stevens Point

Tyler Radke, Green Bay

Kellie Diedrick, Green Bay

Karen Siebers, Neenah

Tracy Felland, Janesville

Brian Simmons, Prairie du Chien

Thomas Fritsche, MD, PhD,
Marshfield

Mary A. Smith, St. Croix Falls

Ben Kaetterhenry, Appleton

Frances Spray-Larson, PhD,
Fort Atkinson

Debra Kieler, Platteville

Janelle Stearns, Eau Claire

Joshua Kropp, Weston

Sarah Stoner, La Crosse

Kathy Lang, Ashland

Cara Tolliver, Sturgeon Bay

Kimber Munson, PhD, Waukesha

Ellen Wirtz, Fond du Lac

Maureen Napierala, Milwaukee

Gundersen Medical Journal • Volume 10, Number 1, December 2017

47

SUR VE I L L A N C E OF W ISCO NSIN O R G ANISMS F OR TRENDS IN A NTIMICROBIA L RESISTA NCE A ND EPI DE M I OLOG Y
REFERENCES

1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in
the United States, 2013. www.cdc.gov/drugresistance/threat-report-2013/pdf/arthreats-2013-508.pdf Accessed 27 April 2017.
2. Munson E. Biographical feature: Clyde Thornsberry, Ph.D. J Clin Microbiol.
2016;54(2):250-253.
3. Munson E, Hueppchen E, Zeman H. Surveillance of Wisconsin Organisms for
Trends in Antimicrobial Resistance and Epidemiology (SWOTARE): introduction
to the program and summary of 2016 geographic variation. Manuscript submitted
for publication.
4. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of
health care-associated infections. N Engl J Med. 2014;370(13):1198-1208.
5. Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of
pneumococcal disease in the United States. Vaccine 2011;29(18):3398-3412.
6. 
Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens
associated with healthcare-associated infections: summary of data reported to
the National Healthcare Safety Network at the Centers for Disease Control and
Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1-14.
7. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobialresistant infections in a Chicago teaching hospital: implications for antibiotic
stewardship. Clin Infect Dis. 2009;49(8):1175-1184.
8. Centers for Disease Control and Prevention (CDC). Vital signs: carbapenemresistant Enterobacteriaceae. MMWR Morbid Mortal Wkly Rep. 2013;62(9):
165-170.
9. Munson E, Block TK, Bowles EJ, et al. Surveillance of Wisconsin antibacterial
susceptibility patterns. WMJ. 2016;115(1):29-36.
10. Clinical and Laboratory Standards Institute (CLSI). M100-S26: Performance
standards for antimicrobial susceptibility testing; twenty-sixth informational
supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
11. Clinical and Laboratory Standards Institute (CLSI). M100-S24: Performance
standards for antimicrobial susceptibility testing; twenty-fourth informational
supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
12. 
Cullen IM, Manecksha RP, McCullagh E, et al. The changing pattern of
antimicrobial resistance within 42,033 Escherichia coli isolates from nosocomial,
community and urology patient-specific urinary tract infections, Dublin, 19992009. BJU Int. 2012;109(8):1198-1206.

14. Jean SS, Coombs G, Ling T, et al. Epidemiology and antimicrobial susceptibility
profiles of pathogens causing urinary tract infections in the Asia-Pacific
region; results from the Study for Monitoring Antimicrobial Resistance Trends
(SMART), 2010-2013. Int J Antimicrob Agents. 2016;47(4):328-334.
15. Lamoth F, Wenger A, Prod’hom G, et al. Comparison of hospital-wide and
unit-specific cumulative antibiograms in hospital- and community-acquired
infection. Infection. 2010;38(4):249-253.
16. 
Zatorski C, Jordan JA, Cosgrove SE, Zocchi M, May L. Comparison of
antibiotic susceptibility of Escherichia coli in urinary isolates from an emergency
department with other institutional susceptibility data. Am J Health Syst Pharm.
72(24):2176-2180.
17. Draper HM, Farland JB, Heidel RE, May LS, Suda KJ. Comparison of bacteria
isolated from emergency department patients versus hospitalized patients. Am J
Health Syst Pharm. 70(23):2124-2128.
18. Swami SK, Banerjee R. Comparison of hospital-wide and age and locationstratified antibiograms of S. aureus, E. coli, and S. pneumoniae: age- and locationstratified antibiograms. SpringerPlus. 2013;2:63.
19. Grignon, Montassier E, Corvec S, et al. Escherichia coli antibiotic resistance in
emergency departments. Do local resistance rates matter? Eur J Clin Microbiol
Infect Dis. 2015;34(3):571-577.
20. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia:
3-year results from the emerging infections and the epidemiology of Iowa
organisms study. J Clin Microbiol. 2002;40(4):1298-1302.
21. Polgreen PM, Beekmann SE, Chen YY, et al. Epidemiology of methicillinresistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a rural
state. Infect Control Hosp Epidemiol. 2006;27(3):252-256.
22. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE!
An update from the Infectious Diseases Society of America. Clin Infect Dis.
2009;48(1):1-12.
23. World Health Organization. WHO publishes list of bacteria for which new
antibiotics are urgently needed. http://www.who.int/mediacentre/news/releases/
2017/bacteria-antibiotics-needed/en/ Accessed 27 April 2017.

13. Smithson A, Ramos J, Bastida MT, et al. Differential characteristics of healthcareassociated compared to community-acquired febrile urinary tract infections in
males. Eur J Clin Microbiol Infect Dis. 2015;34(12):2395-2402.

48

Gundersen Medical Journal • Volume 10, Number 1, December 2017

